Everolimus induced mood changes in breast cancer patients: a case-control study

Conclusions The mTOR inhibitor everolimus induces significant mood alterations in breast cancer patients. The evaluation of psychiatric symptoms is not only mandatory in the context of phase 1, dose-finding studies of PI3K/Akt/mTOR inhibitors, but is also clinically relevant in daily practice.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research